In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Special Issue: Equivalence of Complex Drug Products: Scientific and Regulatory Challenges (vol 1407)

Edited by

Ann NY Acad Sci editorial staff

Special Issue: Equivalence of Complex Drug Products: Scientific and Regulatory Challenges (vol 1407)

Published: November 2017

Volume 1407

Published since 1824, Annals of the New York Academy of Sciences is the Academy’s premier scientific publication.

Learn More


WHO standards for biotherapeutics, including biosimilars: an example of the evaluation of complex biological products

Ivana Knezevic, Elwyn Griffiths

Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation

Amy Barton Pai

Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey

Z. Gulsen Oner, Sarah L.J. Michel, James E. Polli


Equivalence of complex drug products: advances in and challenges for current regulatory frameworks

Leonie Hussaarts, Stefan Mühlebach, Vinod P. Shah, Scott McNeil, Gerrit Borchard, Beat Flühmann, Vera Weinstein, Sesha Neervannan, Elwyn Griffiths, Wenlei Jiang, et al.

How to select a nanosimilar

Alain Astier, Amy Barton Pai, Marco Bissig, Daan J.A. Crommelin, Beat Flühmann, Jean‐Daniel Hecq, Josefien Knoeff, Hans‐Peter Lipp, Alberto Morell‐Baladrón, Stefan Mühlebach


Iron sucrose: assessing the similarity between the originator drug and its intended copies

Tiziana Di Francesco, Erik Philipp, Gerrit Borchard

Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model

Iris Grossman, Sarah Kolitz, Arthur Komlosh, Benjamin Zeskind, Vera Weinstein, Daphna Laifenfeld, Adrian Gilbert, Oren Bar‐Ilan, Kevin D. Fowler, Tal Hasson, et al.